Group sales and earnings

• Homepage
• Group Management Report
• Outlook
• Group sales and earnings

• Contact

  Fresenius SE & Co. KGaA
  Investor Relations & Sustainability
  +49 (0) 6172 608-2485
  ir-fre@fresenius.com

• Related Links

  • Glossary
  • Downloads
  • Personal Data Request

• Share price

  FRESENIUS SE & CO. KGaA

   

   

   

  Data is delayed by 15 minutes.

  Detailed chart

• Library

  • Annual Report 2020 (PDF, 10 MB)
  • Factsheet FY/20 (PDF, 452 KB)

Fresenius continues to expect Group sales to grow organically with a compounded annual growth rate (CAGR) of 4% to 7% during 2020 to 2023. Group net income^1,2 is projected to increase organically with a CAGR of 5% to 9% during 2020 to 2023. Fresenius expects its sales growth and efficiency improvement initiatives as well as Fresenius Kabi’s biosimilarsBiosimilarsA biosimilar is a drug that is “similar” to another biologic drug already approved. business to drive an acceleration of Group earnings growth over that period. Small and medium-sized acquisitions are expected to contribute an incremental CAGR of approx. 1%-point to both sales and net income growth.

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA
² Before special item

COVID-19 will continue to impact Fresenius’ operations in 2021. Current burdens and constraints caused by COVID-19 are expected to recede only in H2/21. The expected improvement in the Group’s relevant business environment from H2/21 is heavily dependent on continuously increasing levels of vaccination coverage. These assumptions are subject to considerable uncertainty.

Fresenius closely monitors the development of COVID-19 case numbers, and the associated various containment measures being enacted in many of the Company’s relevant markets. The Group’s FY/21 guidance does not reflect any potential further containment measures that could have a significant and direct impact on the health care sector without any appropriate compensation.